Discontinued — last reported Q2 '23
Cardinal Health Pharmaceutical — Accumulated goodwill impairment loss remained flat by 0.0% to $829.00M in Q2 2023 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $829.00M to $829.00M. This is a positive signal — lower values indicate better performance for this metric.
An increase signals that past acquisitions have failed to meet performance expectations, potentially indicating poor capital allocation.
The cumulative total of impairment charges recognized against goodwill within the segment over time. This reflects histo...
Investors monitor this to assess the long-term success and valuation accuracy of a company's M&A strategy.
cah_segment_pharmaceutical_accumulated_goodwill_impairment_loss| Q2 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q2 '23 | |
|---|---|---|---|---|---|
| Value | $829.00M | $829.00M | $829.00M | $829.00M | $829.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | +0.0% | +0.0% |